Morin regulates the expression of NF-κB-p65, COX-2 and matrix metalloproteinases in diethylnitrosamine induced rat hepatocellular carcinoma

Chemico-Biological Interactions

Volumn 180, Issue 3, 2009, Pages 353-359

  Sivaramakrishnan, V ^a   Niranjali Devaraj, S ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

COX 2; Hepatocellular carcinoma; Matrix metalloproteinases; Morin; NF B

Indexed keywords

CYCLOOXYGENASE 2; DIETHYLNITROSAMINE; GELATINASE A; GELATINASE B; MORIN; TRANSCRIPTION FACTOR RELA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; HEPATITIS; LIVER CELL CARCINOMA; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; TUMOR VASCULARIZATION; UPREGULATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CYCLOOXYGENASE 2; DIETHYLNITROSAMINE; DOWN-REGULATION; FLAVONOIDS; LIVER NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; RATS; RATS, WISTAR; TRANSCRIPTION FACTOR RELA; TUMOR CELLS, CULTURED;

ANIMALIA; RATTUS;

EID: 67349224725     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.02.004     Document Type: Article

References (41)

1. Zender L., and Kubica S. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma. Onkologie 31 10 (2008) 550-555
2. Garcia M., Jemal A., Ward E.M., Center M.M., Hao Y., Siegel R.L., and Thun M.J. Global Cancer Facts and Figures (2007), American Cancer Society
3. Gomaa A.I., Khan S.A., Toledano M.B., Waked I., and Taylor-Robinson S.D. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J. Gastroenterol. 14 27 (2008) 4300-4308
4. Naugler W.E., and Schwartz J.M. Hepatocellular carcinoma. Dis-a-mon. 54 7 (2008) 432-444
5. Feo F., Pascale R.M., Simile M.M., De Miglio M.R., Muroni M.R., and Calvisi D. Genetic alterations in liver carcinogenesis: implications for new preventive and therapeutic strategies. Crit. Rev. Oncol. 11 1 (2000) 19-62
6. Aiub C.A., Mazzei J.L., Pinto L.F., and Felzenszwalb I. Participation of BER and NER pathways in the repair of DNA lesions induced at low concentrations. Toxicol. Lett. 154 1-2 (2004) 133-142
7. Reh B.D., and Fajen J.M. Worker exposure to nitrosamines in a rubber vehicle sealing plant. Am. Ind. Hyg. Assoc. J. 57 (1996) 918-923
8. Zhou J., Bai R., and Zhu Y. Determination of four tobacco specific nitrosamines in mainstream cigarette smoke by gas chromatography/ion trap mass spectrometry. Rapid Commun. Mass Spectrom. 21 24 (2007) 4086-4092
9. Lubick N. More nitrosamines in drinking water. Environ. Sci. Technol. 40 24 (2006) 7454
10. Théret N., Musso O., Turlin B., Lotrian D., Bioulac-Sage P., Campion J.P., Boudjéma K., and Clément B. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 34 (2001) 82-88
11. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 11 (2006) 1696-1701
12. Lichtinghagen R., Michels D., Haberkorn C.I., Arndt B., Bahr M., Flemming P., Manns M.P., and Boekar K.H. Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J. Hepatol. 34 (2001) 239-247
13. Cusimano, Fodero D., D'Alessandro N., Lampiasi N., Azzolina A., Montalto G., and Cervello M. Potentiation of the antitumor effects of both selective cyclooxgenases-1 and cyclooxygenases-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway. Cancer Biol. Ther. 6 9 (2007) 1461-1468
14. 4-treated rat liver injury. J. Korean Med. Sci. 17 2 (2002) 193-200
15. Liu C.H., Chang S.H., Narko K., Trifan O.C., Wu M.T., Smith E., Haudenschild C., Lane T.F., and Hla T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 276 (2001) 18563-18569
16. Tang T.C., Poon R.T., Lau C.P., Xie D., and Fan S.T. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J. Gastroenterol. 11 13 (2005) 1896-1902
17. Mohammed N.A., Abd El-Aleem S.A., El-Hafiz H.A., and McMahon R.F. Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis. J. Clin. Pathol. 57 4 (2004) 350-354
18. Ramsay R.G., Ciznadija D., Vanevski M., and Mantamadiotis T. Transcriptional regulation of cyclo-oxygenase expression three pillars of control. Int. J. Immunopathol. Pharmacol. 16 (2003) 59-67
19. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich- Pyest E., Urieli-Shoval S., Galun E., and Ben-Neriah Y. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
20. Lu H., Ouyang W., and Huang C. Inflammation, a key event in cancer development. Mol. Cancer Res. 4 (2006) 221-233
21. Elsharkawy A.M., and Mann D.A. Nuclear factor-κB and the hepatic inflammation fibrosis-cancer axis. Hepatology 46 (2007) 590-597
22. Fresco P., Borges F., Diniz C., and Marques M.P. New insights on the anticancer properties of dietary polyphenols. Med. Res. Rev. 26 (2006) 747-766
23. Aggarwal B.B., and Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 71 (2006) 1397-1421
24. Wu T.W., Fung K.P., Yang C.C., and Weisel R.D. Antioxidation of human low density lipoprotein by morin hydrate. Life Sci. 57 3 (1995) PL51-56
25. Denda H., Ura T., Tsujiuchi M., Tsutsumi H., Eimoto Y., Takashima S., Kitazawa T., Kinugasa Y., and Konishi. Possible involvement of arachidonic acid metabolism in phenobarbital promotion of hepatocarcinogenesis. Carcinogenesis 10 10 (1989) 1929-1935
26. Hsiang C.Y., Wu S.L., and Ho T.Y. Morin inhibits 12-O-tetradecanoylphorbol-13-acetate-induced hepatocellular transformation via activator protein 1 signaling pathway and cell cycle progression. Biochem. Pharmacol. 69 11 (2005) 1603-1611
27. Manna S.K., Aggarwal R.S., Sethi G., Aggarwal B.B., and Ramesh G.T. Morin (3,5,7,2′,4′-Pentahydroxyflavone) abolishes nuclear factor-kappaB activation induced by various carcinogens and inflammatory stimuli, leading to suppression of nuclear factor-kappaB-regulated gene expression and up-regulation of apoptosis. Clin. Cancer Res. 13 7 (2007) 2290-2297
28. Tanaka T., Kawabata K., Kakumoto M., Makita H., Ushida J., Honjo S., Hara A., Tsuda H., and Mori H. Modifying effects of a flavonoid morin on azoxymethane-induced large bowel tumorigenesis in rats. Carcinogenesis 20 8 (1999) 1477-1484
29. Kawabata K., Tanaka T., Honjo S., Kakumoto M., Hara A., Makita H., Tatematsu N., Ushida J., Tsuda H., and Mori H. Chemopreventive effect of dietary flavonoid morin on chemically induced rat tongue carcinogenesis. Int. J. Cancer 83 3 (1999) 381-386
30. Tanaka T., Kawabata K., Honjo S., Kohno H., Murakami M., Shimada R., Matsunaga K., Yamada Y., and Shimizu M. Inhibition of azoxymethane-induced aberrant crypt foci in rats by natural compounds, caffeine, quercetin and morin. Oncol Rep. 6 6 (1999) 1333-1340
31. Subhashinee Wijeratne S.K., Mamdouh Abou-Zaid M., and Shahidi F. Antioxidant polyphenols in almond and its coproducts. J. Agri. Food Chem. 54 (2006) 312-318
32. Romero I., Paez A., Ferruelo A., Lujan M., and Berenguer A. Polyphenols in red wine inhibit the proliferation and induce apoptosis of LNCaP cells. BJU Int. 89 (2002) 950-954
33. Windholz M. The Merck Index. 11th ed. (1989), Merck and Co., Inc. pp. 986-987
34. Sivaramakrishnan V., Shilpa P.N., Praveen Kumar V.R., and Niranjali Devaraj S. Attenuation of N-nitrosodiethylamine-induced hepatocellular carcinogenesis by a novel flavonol-morin. Chem. Biol. Interact. 171 1 (2008) 79-88
35. Liota L.A., and Stetler-Stevenson W.G. Gelatin zymography protocol. Canc. Biol. 1 (1990) 96-106
36. Cervello M., and Montalto G. Cyclooxygenases in hepatocellular carcinoma. World J. Gastroenterol. 12 32 (2006) 5113-5121
37. Breinig M., Schirmacher P., and Kern M.A. Cyclooxygenase-2 (COX-2)-a therapeutic target in liver cancer?. Curr. Pharm. Des. 13 32 (2007) 3305-3315
38. Zhao Q.T., Yue S.Q., Cui Z., Wang Q., Cui X., Zhai H.H., Zhang L.H., and Dou K.F. Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis. Life Sci. 80 5 (2007) 484-492
39. Chantrian C.F., Henriet P., Jodele S., Emonard H., Feron O., Courtoy P.J., DeClerck Y., and Marbaix E. Mechanisms of pericyte recruitment in tumor angiogenesis: a new role for metalloproteinases. Eur. J. Cancer 42 3 (2006) 310-318
40. Bjorklund M., and Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim. Biophys. Acta 1755 1 (2005) 37-69
41. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., and Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2 (2000) 737-744